他汀类药物与心血管疾病一级预防中不良事件的关联:系统综述及配对、网络和剂量反应荟萃分析
该系统综述纳入62项随机对照试验、120 456名无心血管疾病史的成人,评估他汀类药物与不良事件的关联。他汀与自报肌肉症状、肝功能障碍、肾功能不全和眼部疾病风险轻度增加相关,但与临床确诊的肌肉疾病或糖尿病无关,且风险增加不超过其主要心血管事件风险的降低。不同他汀类型间差异较少,剂量反应关系大多不确定。
要点
- 他汀一级预防中不良事件绝对风险增加较小,获益-伤害平衡总体有利。
- 他汀与自报肌肉症状、肝功能障碍、肾功能不全和眼部疾病风险轻度增加相关。
- 他汀与临床确诊的肌肉疾病或糖尿病无显著关联。
核心结论
- 他汀用于心血管疾病一级预防时,归因于他汀的不良事件风险较低,且不超过其预防心血管疾病的疗效,获益-伤害平衡总体有利。
- 支持在开始治疗前根据安全考虑调整他汀类型或剂量的证据有限。
研究设计与样本
- 系统综述与荟萃分析,纳入62项随机对照试验,共120 456名无心血管疾病史的成人,平均随访3.9年。
- 检索Medline、Embase和Cochrane Central Register of Controlled Trials,截至2020年8月。
主要发现
- 他汀与自报肌肉症状风险增加相关(21项试验,OR 1.06,95%CI 1.01-1.13;绝对风险差异每10 000患者治疗1年增加15例,95%CI 1-29)。
- 他汀与肝功能障碍风险增加相关(21项试验,OR 1.33,95%CI 1.12-1.58;绝对风险差异8,95%CI 3-14)。
- 他汀与肾功能不全风险增加相关(8项试验,OR 1.14,95%CI 1.01-1.28;绝对风险差异12,95%CI 1-24)。
- 他汀与眼部疾病风险增加相关(6项试验,OR 1.23,95%CI 1.04-1.47;绝对风险差异14,95%CI 2-29)。
- 他汀与临床确诊的肌肉疾病或糖尿病无显著关联。
关键数值与推荐
- 阿托伐他汀、洛伐他汀和瑞舒伐他汀各自与某些不良事件相关,但不同他汀类型间显著差异较少。
- 阿托伐他汀对肝功能障碍的影响呈现Emax剂量反应关系,其他他汀及不良事件的剂量反应关系不确定。
临床怎么用
- 一级预防中使用他汀时,应认识到不良事件绝对风险增加较小,总体获益大于风险。
- 目前证据尚不足以支持在开始治疗前常规根据安全考虑调整他汀类型或剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the associations between statins and adverse events in primary prevention of cardiovascular disease and to examine how the associations vary by type and dosage of statins. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Studies were identified from previous systematic reviews and searched in Medline, Embase, and the Cochrane Central Register of Controlled Trials, up to August 2020. REVIEW METHODS: Randomised controlled trials in adults without a history of cardiovascular disease that compared statins with non-statin controls or compared different types or dosages of statins were included. MAIN OUTCOME MEASURES: Primary outcomes were common adverse events: self-reported muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, renal insufficiency, diabetes, and eye conditions. Secondary outcomes included myocardial infarction, stroke, and death from cardiovascular disease as measures of efficacy. DATA SYNTHESIS: A pairwise meta-analysis was conducted to calculate odds ratios and 95% confidence intervals for each outcome between statins and non-statin controls, and the absolute risk difference in the number of events per 10 000 patients treated for a year was estimated. A network meta-analysis was performed to compare the adverse effects of different types of statins. An Emax model based meta-analysis was used to examine the dose-response relationships of the adverse effects of each statin. RESULTS: 62 trials were included, with 120 456 participants followed up for an average of 3.9 years. Statins were associated with an increased risk of self-reported muscle symptoms (21 trials, odds ratio 1.06 (95% confidence interval 1.01 to 1.13); absolute risk difference 15 (95% confidence interval 1 to 29)), liver dysfunction (21 trials, odds ratio 1.33 (1.12 to 1.58); absolute risk difference 8 (3 to 14)), renal insufficiency (eight trials, odds ratio 1.14 (1.01 to 1.28); absolute risk difference 12 (1 to 24)), and eye conditions (six trials, odds ratio 1.23 (1.04 to 1.47); absolute risk difference 14 (2 to 29)) but were not associated with clinically confirmed muscle disorders or diabetes. The increased risks did not outweigh the reduction in the risk of major cardiovascular events. Atorvastatin, lovastatin, and rosuvastatin were individually associated with some adverse events, but few significant differences were found between types of statins. An Emax dose-response relationship was identified for the effect of atorvastatin on liver dysfunction, but the dose-response relationships for the other statins and adverse effects were inconclusive. CONCLUSIONS: For primary prevention of cardiovascular disease, the risk of adverse events attributable to statins was low and did not outweigh their efficacy in preventing cardiovascular disease, suggesting that the benefit-to-harm balance of statins is generally favourable. Evidence to support tailoring the type or dosage of statins to account for safety concerns before starting treatment was limited. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020169955.
引用
- Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021. PMID: 34261627. doi:10.1136/bmj.n1537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。